QQ客服 官方微博 反馈留言

	SKLB023 as an iNOS inhibitor alleviated liver fibrosis by inhibiting the TGF-beta/Smad signaling pathway
	Zhang, Jinhang; Li, Yanping; Liu, Qinhui; Li, Rui; Pu, Shiyun; Yang, Lina; Feng, Yanhuan; Ma, Liang
刊名	RSC ADVANCES
	2018
卷号	Vol.8 No.54页码:30919-30924
ISSN号	2046-2069
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/1835857
专题	四川大学
作者单位	1.Sichuan Univ, Dept Pharm, Lab Clin Pharm & Adverse Drug React, West China Hosp,Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China 2.Sichuan Univ, Div Nephrol, Kidney Res Lab, West China Hosp, Chengdu 610041, Sichuan, Peoples R China
推荐引用方式 GB/T 7714	Zhang, Jinhang,Li, Yanping,Liu, Qinhui,et al. SKLB023 as an iNOS inhibitor alleviated liver fibrosis by inhibiting the TGF-beta/Smad signaling pathway[J]. RSC ADVANCES,2018,Vol.8 No.54:30919-30924.
APA	Zhang, Jinhang.,Li, Yanping.,Liu, Qinhui.,Li, Rui.,Pu, Shiyun.,...&Ma, Liang.(2018).SKLB023 as an iNOS inhibitor alleviated liver fibrosis by inhibiting the TGF-beta/Smad signaling pathway.RSC ADVANCES,Vol.8 No.54,30919-30924.
MLA	Zhang, Jinhang,et al."SKLB023 as an iNOS inhibitor alleviated liver fibrosis by inhibiting the TGF-beta/Smad signaling pathway".RSC ADVANCES Vol.8 No.54(2018):30919-30924.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。